Sight’s analyzer machine, "OLO", performs a Complete Blood Count, a commonly ordered blood test. It can complete results in minutes. It’s compact: designed to be used in a mobile capacity.
Their analyzers create a digital version of blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by algorithms. Sight’s first product was focused on detecting Malaria, used in 24 countries, and has delivered almost 1 million tests to date.
History
Their OLO product came to fruition five years ago, with the introduction of Sight’s advanced algorithms to detect Malaria.
The solution enabled quick diagnoses using digital fluorescent microscopy and computer vision algorithms.
Timeline
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
27,800,000
February 2019
10,000,000
March 2019
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
January 4, 2021
WebWire
Sight Diagnostics ®, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, was announced today as one of the winners in the Genesis Prize and Start-Up Nation Central technology competition for its efforts in combating the COVID-19 pandemic. The competition honored Genesis Prize laureate Natan Sharansky, who donated his prize award to fighting Covid-19. Out of the hundreds of Israeli-based companies under consideration, Sight was selected as one of the ten winn...
Frederic Lardinois
August 5, 2020
TechCrunch
Sight Diagnostics, the Israel-based health-tech company behind the FDA-cleared OLO blood analyzer, today announced that it has raised a $71 million Series D round with participation from Koch Disruptive Technologies, Longliv Ventures (which led its Series C round)and crowd-funding platform OurCrowd. With this, the company has now raised a total of $124 million, though the [...]
August 5, 2020
WebWire
Sight Diagnostics ® , the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies , Longliv Ventures and OurCrowd [
March 18, 2020
WebWire
Sight and Sheba Tel Hashomer today announced their new collaboration aimed at mitigating the risk of contamination by COVID-19. Sight's OLO blood analyzer will provide rapid CBC (complete blood count) results in a dedicated lab within Israel's flagship government-run hospital, to process samples of infected patients who are being monitored and treated in a separate field hospital. Prior to deploying OLO for coronavirus patient testing, Sight ran a two-month evaluation at the central lab o...
September 23, 2019
WebWire
Sight Diagnostics, the company working to provide patients with lab-grade blood testing results in minutes, today announces two strategic hires to drive global growth. The expansion of the team supports Sight's clinical progress in the US as the company recently completed clinical trials and is working toward commercialization. Sight is the maker of OLO, a blood analyzer that performs diagnostics from two drops of blood with the goal of improving efficiencies and the patient experience....
References
Is a
Company attributes
Industry
Location
CEO
Founder
Crunchbase
Founded date
2011
Total funding amount (USD)
62,800,000
Latest funding round date
March 2019
Categories
Related Topics
Contributors
- 1
Nico Faraguna
Video game fan with a passion for technology and pop culture. I make plastic rock climbing routes, too. - 2
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 3
Lax Mariappan
Technopreneur, Open source enthusiast, author, speaker. Co-founder of Eternus Global. Crafting applications for the medical industry. - 4
Aime Anne Nisay
QA Engineer of web and mobile applications